Michael Schultz
About Michael Schultz
Michael Schultz is a Global Trial Manager at Bristol Myers Squibb with extensive experience in clinical research, particularly in oncology.
Title
Michael Schultz holds the position of Global Trial Manager at Bristol Myers Squibb. His role involves overseeing the planning and execution of global clinical trials, ensuring compliance with regulatory standards and the achievement of study objectives.
Previous Positions
Michael Schultz previously served as Senior Oncology Project Manager at Sarah Cannon in 2022 for three months. Before that, he was Clinical Project Manager at Biosplice Therapeutics from 2021 to 2022 for nine months. He worked extensively at Samumed, LLC holding multiple positions such as Associate Clinical Project Manager, Senior Clinical Research Associate Manager, and Clinical Research Associate Manager, from 2014 to 2022. Prior to that, he was employed as a Senior Clinical Research Associate at PPD from 2012 to 2014 and as Clinical Research Associate II at Synteract, Inc. from 2006 to 2012.
Education and Expertise
Michael Schultz studied at San Diego State University from 1997 to 2002. He has extensive experience in managing clinical trials, particularly in the field of oncology, demonstrated by his roles in various organizations. His career trajectory shows a strong background in clinical research management.
Clinical Research Management
Michael Schultz has a comprehensive background in clinical research management. Throughout his career, he has held multiple senior positions, particularly at Samumed, LLC. His responsibilities have included managing clinical trials, developing clinical strategies, and ensuring compliance with regulatory requirements. His expertise extends across different areas of clinical research, highlighting his strong leadership in the field.
Professional Network
Having worked primarily in the Greater San Diego Area, Michael Schultz has established a solid professional network within the clinical research community in this region. His long-standing presence in the field since 2006 has enabled him to build strong connections and contribute to the area's clinical research initiatives.